Tumor-absorbed dose predicts progression-free survival following 131I-tositumomab radioimmunotherapy

Journal of Nuclear Medicine

Volumn 55, Issue 7, 2014, Pages 1047-1053

  Dewaraja, Yuni K ^a   Schipper, Matthew J ^b   Shen, Jincheng ^b   Smith, Lauren B ^a   Murgic, Jure ^c   Savas, Hatice ^a   Youssef, Ehab ^a   Regan, Denise ^a   Wilderman, Scott J ^b   Roberson, Peter L ^b   Kaminski, Mark S ^a   Avram, Anca M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c KBC Zagreb   (Croatia)

Author keywords

Dosimetry; Non Hodgkin lymphoma; Progression free survival; Radioimmunotherapy; SPECT CT

Indexed keywords

BORTEZOMIB; TOSITUMOMAB I 131; IODINE-131 ANTI-B1 ANTIBODY; MONOCLONAL ANTIBODY;

ADOLESCENT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORRELATIONAL STUDY; DOSIMETRY; FEMALE; HUMAN; MALE; MONTE CARLO METHOD; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PATIENT SELECTION; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE ESCALATION; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THREE DIMENSIONAL IMAGING; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME; VERY ELDERLY; ADULT; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; PATHOLOGY; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL; PROCEDURES; RADIOGRAPHY; RADIOMETRY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MONTE CARLO METHOD; PRECISION MEDICINE; RADIATION DOSAGE; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84904093820     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.136044     Document Type: Article

References (26)

1. 131I-tositumomab in clinical practice. J Nucl Med. 2007;48:1767-1776.
2. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-449.
3. DeNardo GL, Denardo SJ, Balhorn R. Update: systemic radiotherapy can cure lymphoma - a paradigm for other malignancies? Cancer Biother Radiopharm. 2008;23:383-397.
4. 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med. 2003;44:260-268.
5. 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. J Nucl Med. 2010;51:1155-1162.
6. 131I-tositumomab therapy of previously untreated lymphoma patients. J Nucl Med. 2003;44:457-464. (Pubitemid 39586025)
7. Wilderman SJ, Dewaraja Y. Method for fast CT/SPECT-based 3D Monte Carlo absorbed dose computations in internal emitter therapy. IEEE Trans Nucl Sci. 2007;54:146-151. (Pubitemid 46375854)
8. Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol. 1985;58:515-528. (Pubitemid 15018411)
9. Roberson PL, Amro H, Wilderman SJ, et al. Bio-effect model applied to 131 I radioimmunotherapy of refractory non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2011;38:874-883.
10. Cheng L, Hobbs RF, Segars PW, Sgouros G, Frey EC. Improved dose-volume histogram estimates for radiopharmaceutical therapy by optimizing quantitative SPECT reconstruction parameters. Phys Med Biol. 2013;58:3631-3647.
11. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586. (Pubitemid 350002966)
12. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23:7565-7573. (Pubitemid 46291820)
13. Schipper MJ, Koral KF, Avram AM, Kaminski MS, Dewaraja YK. Prediction of therapy tumor-absorbed dose estimates in I-131 radioimmunotherapy using tracer data via a mixed-model fit to time activity. Cancer Biother Radiopharm. 2012;27:403-411.
14. Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res. 2004;10:7792-7798. (Pubitemid 39587516)
15. Dewaraja YK, Frey EC, Sgouros G, et al. MIRD pamphlet no. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med. 2012;53:1310-1325.
16. Dewaraja Y, Avram AM, Roberson P, et al. Tumor absorbed dose predicts progression free survival (PFS) following I-131 radioimmunotherapy (RIT) [abstract]. J Nucl Med. 2013;54(suppl 2):16P.
17. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000;18:1316-1323. (Pubitemid 30159851)
18. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19:3918-3928. (Pubitemid 32912019)
19. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259-1266.
20. Girinsky T, Guillot-Vals D, Koscielny S, et al. A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. Int J Radiat Oncol Biol Phys. 2001;51:148-155. (Pubitemid 32758874)
21. Haas RL, Poortmans P, De Jong D, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol. 2003;21:2474-2480. (Pubitemid 46606327)
22. Murthy V, Thomas K, Foo K, et al. Efficacy of palliative low-dose involved-field radiation therapy in advanced lymphoma: a phase II study. Clin Lymphoma Myeloma. 2008;8:241-245.
23. Radford IR. Radiation response of mouse lymphoid and myeloid cell lines. Part I. Sensitivity to killing by ionizing radiation, rate of loss of viability, and cell type of origin. Int J Radiat Biol. 1994;65:203-215. (Pubitemid 24097193)
24. Radford IR, Murphy T, Radley J, Ellis S. Radiation response of mouse lymphoid and myeloid cell lines. Part II. Apoptotic death is shown by all lines examined. Int J Radiat Biol. 1994;65:217-227. (Pubitemid 24097194)
25. Eriksson D, Riklund K, Johansson L, Strigbrand T. Radiation induced cell deaths. In: Stigbrand T, Carlsson J, Adams GP, eds. Targeted Radionuclide Tumor Therapy: Biological Aspects. Berlin, Germany: Springer; 2008:215-248.
26. Wilderman SJ, Roberson P, Bolch W, Dewaraja Y. Investigation of effect of variations in bone fraction and red marrow cellularity on bone marrow dosimetry in radio-immunotherapy. Phys Med Biol. 2013;58:4717-4731.